{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:14:11Z","timestamp":1770070451173,"version":"3.49.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the European Society of Cardiology Congress 2007. Unpublished reports should be considered as preliminary data, as analyses may change in the final publication.<\/jats:p>\n                  <jats:p>In the 3CPO study, non-invasive ventilation produced a more rapid resolution of symptoms in patients hospitalised with acute cardiogenic pulmonary oedema; but had no effect on survival, compared to standard oxygen therapy. The ALOFT study showed that the selective oral renin inhibitor aliskiren reduces plasma BNP levels and is well tolerated in patients with heart failure receiving ACE inhibitors or ARBs, although the study was not powered to show clinical benefit. In the PROSPECT study, no echocardiographic measure of mechanical dyssynchrony was identified that was useful for identifying patients more or less likely to respond to CRT. Low dose atorvastatin reduced the incidence of sudden cardiac death in a small placebo controlled study of patients with advanced chronic heart failure.<\/jats:p>","DOI":"10.1016\/j.ejheart.2007.09.005","type":"journal-article","created":{"date-parts":[[2007,9,25]],"date-time":"2007-09-25T07:07:59Z","timestamp":1190704079000},"page":"1070-1073","source":"Crossref","is-referenced-by-count":51,"title":["Clinical Trials Update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and Statins for Heart Failure"],"prefix":"10.1093","volume":"9","author":[{"given":"John G.F.","family":"Cleland","sequence":"first","affiliation":[{"name":"Department of Cardiology, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Tageldien","family":"Abdellah","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Khaleva","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison P.","family":"Coletta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,10,1]]},"reference":[{"key":"2026020203494361000_ejhf2007-09-005-bib-0001","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1001\/jama.294.24.3124","article-title":"Noninvasive ventilation in acute cardiogenic pulmonary edema","volume":"294","author":"Masip","year":"2005","journal-title":"JAMA"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0002","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0195-668X(02)00823-0","article-title":"The EuroHeart Failure survey programme \u2014 a survey on the quality of care among patients with heart failure in Europe","volume":"24","author":"Cleland","year":"2003","journal-title":"Eur Heart J"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0003","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00129784-200303060-00002","article-title":"Therapeutic potential of renin inhibitors in the management of cardiovascular disorders","volume":"3","author":"Stanton","year":"2003","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0004","article-title":"Neurohumoral effects of the new orally active renin inhibitor aliskiren in chronic heart failure","author":"Seed","journal-title":"Eur J Heart Fail in press"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0007","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ncpcardio0794","article-title":"Cardiac resynchronisation therapy or atrio-biventricular pacing \u2014 what should it be called?","volume":"4","author":"Cleland","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0008","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronisation on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0009","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/jama.289.6.730","article-title":"Cardiac resynchronisation ad death from progressive heart failure: a meta-analysis or randomised controlled trials","volume":"289","author":"Bradley","year":"2003","journal-title":"JAMA"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0010","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/eurheartj\/ehi246","article-title":"How to predict response to cardiac resynchronisation therapy?","volume":"26","author":"Bax","year":"2005","journal-title":"Eur Heart J"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0011","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ahj.2005.06.024","article-title":"Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the multicenter InSync randomised clinical evaluation (MIRACLE) and multicenter InSync ICD randomised clinical evaluation (MIRACLE-ICD) trials","volume":"151","author":"Pires","year":"2006","journal-title":"Am Heart J"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0012","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ahj.2004.12.013","article-title":"Predictors of response to cardiac resynchronisation therapy (PROSPECT) study design","volume":"149","author":"Yu","year":"2005","journal-title":"Am Heart J"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0013","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/eurheartj\/ehm192","article-title":"Predictors of treatment response with cardiac resynchronisation therapy in patients with heart failure characterised by dyssynchrony: a predefined analysis from the CARE-HF trial","volume":"28","author":"Richardson","year":"2007","journal-title":"Eur Heart J"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0014","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0015","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long term intervention with pravastatin in ischemic heart disease (LIPID) study group","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0017","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ahj.2007.01.029","article-title":"The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality after the diagnosis of left ventricular systolic dysfunction","volume":"153","author":"Loh","year":"2007","journal-title":"Am Heart J"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0018","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1071-9164(97)90022-1","article-title":"The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease","volume":"3","author":"Kjekshus","year":"1997","journal-title":"J Card Fail"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0019","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ejheart.2004.03.001","article-title":"Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure","volume":"6","author":"Tavazzi","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026020203494361000_ejhf2007-09-005-bib-0020","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ejheart.2005.09.005","article-title":"A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics","volume":"7","author":"Kjekshus","year":"2005","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ejheart.2007.09.005","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/9\/10\/1070\/66616129\/eurjhf_9_10_1070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/9\/10\/1070\/66616129\/eurjhf_9_10_1070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:49:49Z","timestamp":1770022189000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/9\/10\/1070\/8443786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,1]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2007,10,1]]},"published-print":{"date-parts":[[2007,10,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ejheart.2007.09.005","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,10]]},"published":{"date-parts":[[2007,10,1]]}}}